Background: Selective serotonin-reuptake inhibitors (SSris) are the most commonly prescribed antidepressants. Previous studies have suggested that SSris may increase the risk of birth defects, including clubfoot. Using data from a population-based case-control study, we evaluated whether SSri use increased the risk of clubfoot. Methods: Mothers were interviewed within 1 year after delivery about sociodemographic factors, pregnancy events, and exposures. they were specifically asked if they experienced depression or anxiety or if they took any of the following SSris: citalopram, escitalopram, fluvoxamine, paroxetine, sertraline, or fluoxetine. We used logistic regression models to calculate odds ratios (Ors) and 95% confidence intervals (cis).
I n the United States, approximately 5%-13% of pregnant women use antidepressants for depression. 1-3 the most commonly prescribed class of antidepressants is selective serotonin-reuptake inhibitors (SSris). 1, 2 However, in recent years, concern has been raised that SSris may increase the risk of birth defects when taken during pregnancy. 1, [4] [5] [6] [7] [8] talipes equinovarus, or clubfoot, is one such birth defect that has been linked with SSri use. 4, 7 the lower limbs begin to form their adult positions in the early weeks of gestation. initially, the soles of the feet are facing each other and the knees extend outward. Beginning in the 9th week after the last menstrual period, the legs begin to rotate inward almost 90 degrees, bringing the big toe into a medial position. 9, 10 clubfoot is a structural malformation that occurs when the lower limbs fail to rotate correctly; it results in the feet remaining in their early fetal position, with one or both feet turning inward and downward. Structural clubfoot is distinguished from positional clubfoot in that the foot cannot be moved into a normal position; additionally, positional clubfoot is believed to result from uterine constraint. 11, 12 the prevalence of structural clubfoot is approximately 1 per 1000 births. 13, 14 to date, 2 studies have assessed the risk of clubfoot in relation to SSri use. 4, 7 the first reported a two-fold increase in the risk when SSris were used in the first trimester, and the risk was highest with paroxetine use. 4 the second study observed a 50% increase in risk and similarly found an elevated risk with paroxetine use. 7 the objective of our study was to evaluate whether SSri use in early pregnancy increased the risk of structural clubfoot in the fetus. in addition, we assessed the role of depression and the risk of clubfoot, independent of SSri use.
METHODS

Study Design
a population-based case-control study of structural clubfoot was conducted between 2006 and 2011 by the Slone epidemiology center at Boston University. its objective was to identify risk factors for clubfoot. the study has been previously described in detail. 15 Briefly, case infants who were less than 1 year of age were identified from birth defect registries in Massachusetts, north carolina, and new York. cases were eligible for the study if they had a diagnosis of talipes equinovarus ("clubfoot") without a known inherited syndrome, chromosomal anomaly, Potter syndrome, bilateral renal agenesis, amniotic bands, arthrogryposis, or neural tube defect, as reported by the mother, the state birth defects registry, or the medical record. Diagnosis of structural clubfoot was confirmed primarily by orthopedic records (77%); when medical records were not available, maternal report of 3 or more castings for the clubfoot was used to confirm a true structural clubfoot (23%). the sensitivity of self-reported clubfoot was high in our study, with case mothers reporting 3 or more casts in 98% of orthopedic-confirmed clubfoot cases. this analysis was restricted to the 95% of cases with only clubfoot and no other major structural malformations. eligible controls consisted of infants with no major malformations or foot problems, drawn from the same birth population as cases and selected from either birth certificates (Massachusetts and north carolina) or hospital medical records (new York). the institutional review boards at Boston University and the state health departments in Massachusetts, north carolina, and new York approved the study protocol. telephone interviews were conducted by trained nurses within 1 year after delivery. a translation service with medical interpreters was used by the nurses when interviewing mothers who did not speak english. the interview consisted of questions on sociodemographic factors, behaviors during pregnancy, dietary history, reproductive and medical history, and reported illnesses and medications. a tiered approach was used in obtaining information on illnesses and medications. Women were first asked if they experienced any occurrences of "depression or anxiety" in the month before their pregnancy through the end of pregnancy. if a mother responded positively, the dates of depression or anxiety and any medications used, including type and timing, were recorded. independent of their responses to the illness questions, mothers were questioned about any medications they took and were prompted with names of specific medications, including "celexa" (citalopram), "lexapro" (escitalopram), "Prozac" (fluoxetine), "luvox" (fluvoxamine), "Paxil" (paroxetine), and "Zoloft" (sertraline). if a mother reported using any medications, the timing and indication for use were noted.
Exposure
For this analysis, the exposure window of interest was the 2nd and 3rd lunar months after the last menstrual period, as this is the etiologically relevant time period for the development of clubfoot. We created 2 exposure definitions; the primary exposure group consisted of women who reported using an SSri for a period of more than 30 days in in the 2nd and 3rd lunar months, whereas the secondary exposure group consisted of women who reported SSris for a period of ≤30 days in the exposure window.
to incorporate maternal reports of depression or anxiety (henceforth referred to as "depression") that may have occurred anytime in the month before or during pregnancy, we created the following mutually exclusive categories: (1) no depression was reported and no antidepressant medication was used at any time in pregnancy (reference group); (2) depression was reported and an SSri treatment was used for a >30-day period in lunar months 2-3; (3) depression was reported and an SSri treatment was used for a period of ≤30 days in the exposure window; (4) depression was reported and SSri treatment occurred only outside the lunar month 2-3 window; (5) depression was reported and a non-SSri medication was used in lunar months 2-3; and (6) depression was reported and no medications were used to treat the depression during pregnancy. if a mother reported taking both an SSri and a non-SSri for depression (n = 36), she was included in category 2, 3, or 4 depending on timing and duration of use. We excluded 42 women who took non-SSris outside of the lunar month 2-3 window and did not take an SSri during pregnancy because their patterns of use and indications varied widely. also, mothers who reported only herbal treatments for depression (eg, St John's wort) or taking antidepressants for reasons other than depression (eg, smoking cessation or attention deficit disorder) were excluded from the analysis.
Statistical Analysis
Sociodemographic and behavioral factors were obtained from the interview and were assessed for cases and controls. We used logistic regression models to calculate odds ratios (Ors) and 95% confidence intervals (cis). Potential confounders that were assessed included maternal race, education, age, smoking, alcohol intake, body mass index (BMi), parity, infant sex, and study center. We added covariates to the model one at a time, and factors that changed the crude estimate by more than 10% were kept in the final model. a subanalysis was conducted restricting cases and controls to those with no family history of clubfoot in a first-degree relative. although all infants with major structural malformations other than clubfoot were removed from the analysis, some infants did have unconfirmed "heart murmurs" reported; therefore, because of previous reports of an association between SSris and heart defects, 4,7,16 a separate analysis was conducted removing cases and controls with a reported heart murmur.
RESULTS
Mothers of 3298 eligible controls and 1323 eligible cases
were approached for the study. among controls, 954 could not be contacted because of missing telephone numbers or nonresponse, 2,091 were interviewed, 243 refused participation, and 10 were ineligible because of death, incarceration, living abroad, lack of interpreter, or having previously participated in a similar study. in addition, 54 control mothers reported their child had a congenital anomaly or foot problem and were consequently excluded from the study, resulting in 2037 controls. among the cases, 286 could not be contacted, 955 were interviewed, and 82 refused participation. Of the interviewed cases, 269 were excluded because of ineligible diagnoses (arthrogryposis, amniotic bands, syndromes, severe oligohydramnios, surrogate mother, and questionable clubfoot) and 8 with ineligible age. the overall response rates for cases and controls were 72% and 64%, respectively. after restriction to cases with only clubfoot and no other major structural malformations, a total of 646 confirmed cases were eligible.
Of the 646 cases and 2037 controls, mothers of 6 cases and 8 controls took antidepressants for reasons other than depression/anxiety and were excluded (only 4 of these women reported use in the exposure window); mothers of 3 controls took only herbal remedies for depression/anxiety and were also excluded. in addition, 42 women who took non-SSris outside of the lunar month 2-3 window were excluded. thus, 622 case and 2002 controls were included in this analysis.
compared with control mothers, mothers of cases were more likely to be overweight, nulliparous, and to have smoked during pregnancy, and these infants were more likely to be male (table 1) . When sociodemographic and behavioral factors were considered among control mothers according to exposure status, smokers were more likely to report depression (table 2 ). in addition, among controls with depression, SSri treatment was more common in women who were White non-Hispanic, multiparous, and obese. the use of SSris among control mothers declined during pregnancy, starting in the 3rd lunar month (Figure 1 ). the specific SSris reported by control mothers varied over the course of the study; paroxetine was reported only in the first study year ( Figure 2 ).
More mothers of cases (24%) reported depression, independent of treatment, than did mothers of controls (17%) ( table 3) . among the women who reported depression, SSri use for a period of more than 30 days was higher among cases (5%) than controls (3%) (table 3). SSri use for a period of ≤30 days in the exposure window was also slightly more common in cases (2%) than controls (1%). in contrast, the use of SSri medications outside the lunar month 2-3 window was similar for cases and controls (1% each), as was the use of non-SSri medications in the exposure window (1% each). the following medications were reported by mothers who used a non-SSri medication for depression/anxiety: alprazolam, buprenorphine, bupropion, buspirone, clonazepam, duloxetine, gabapentin, haloperidol, lithium, lorazepam, paliperidone, quetiapine, venlafaxine, zolpidem, and a not otherwise-specified sleep or sedative medication.
We assessed which covariates changed exposure Ors by >10%. Maternal alcohol consumption changed the Or for SSri use for a ≤30-day period in lunar months 2-3; maternal BMi changed the Or for SSri use outside the lunar month 2-3 window; and maternal smoking changed the Or for non-SSri medication in lunar months 2-3. therefore, smoking (referent group: nonsmoker in lunar months 2-3), alcohol (referent: no use in lunar months 2-3), and BMi (referent group: 18.5-24.9 kg/m 2 ) were included in all final models.
as noted in table 3, the adjusted Or for clubfoot and maternal depression with SSri use for a >30-day period in lunar the risk for women reporting depression with no drug treatment was modestly elevated (1.3 [1.0-1.7]). the most commonly reported SSri drug was sertraline, with cases (2%) reporting more use than controls (1%) (table 4 and Figure 2 ). adjusted Ors were as follows: for sertraline, 1.6 (13 exposed cases [95% ci = 0.8-3.2]); for paroxetine, 9.2 (3 exposed cases [0.7-484.6]); and for escitalopram, 2.9 (9 exposed cases [1.1-7.2]). When the data were restricted to the 551 cases and 1987 controls with no family history of clubfoot, the results did not change substantially (for SSri use for >30 days in lunar months 2-3, adjusted Or = 1.7 [95% ci = 1.0-2.7]). in addition, the results did not change when the data were restricted to the 596 cases and 1996 controls without heart murmurs (for SSri use for >30 days in lunar months 2-3, adjusted Or = 1.8 [1.1-2.9]).
DISCUSSION
Overall, our data suggest an increased risk of clubfoot in the offspring of women who use SSris for a substantial period of time in the 2nd and 3rd lunar months of pregnancy but no increased risk for use for shorter durations or outside that critical developmental window. Drug-specific risks varied widely, but where numbers were sufficient to produce stable estimates, we observed increased risks for sertraline and for escitalopram; the large risk observed for paroxetine was based on only 3 exposed cases and 1 exposed control.
Our findings support those previously reported for SSri use and the risk of clubfoot. louik and colleagues 4 observed a 2.2-fold (95% ci = 1.4-3.6) increased risk of clubfoot with any SSri use in the first trimester. Similar to our findings, they found elevated risks with use of sertraline (adjusted Or = 2.4 [0.9-6.2]) and paroxetine (5.8 [2.6-13.1]), whereas no elevated risk was associated with fluoxetine (0.8 [0.2-2.5]). their finding of an increased risk with citalopram (2.7 [0.5-13.1]) was higher than our observed finding (0.9 [0.2-3.4]). their study was similar to ours in that it used a multicenter case-control design and exposure information came from maternal reports.
One key difference was the timing of the exposure window because our study focused solely on clubfoot; we narrowed the window to the 2nd and 3rd lunar months, whereas louik et al used a window of 28 days before conception through the 4th lunar month. in addition, our study data were population based, with cases coming from registries, whereas their data used a combination of hospital-based and population-based sources for cases. Our cases had structural clubfoot confirmed by an orthopedist or information on treatment, whereas the louik et al study used maternal reports with or without medical record diagnoses for case confirmation.
colvin and colleagues 7 . their exposure window was broader than ours and included the first trimester. in addition, because colvin et al 7 used administrative databases to obtain exposure information, it is possible that mothers who received a prescription for an SSri medication may not have taken it. thus, use of a prescription database to obtain exposure information may have led to some exposure misclassification, which would likely bias findings toward the null.
in the current and previous studies, the SSri with the strongest association with clubfoot has been paroxetine, where large but unstable risks estimates were observed. it is of note that use of paroxetine in pregnancy has been decreasing since the US Food and Drug administration issued a warning about such use in 2005. 3 the increased risks we identified when SSris were used for a period of more than 30 days, combined with the lack of an association for use 30 days or less, suggests that consistent exposure in the etiologic window may be required to increase the risk of clubfoot. When we examined SSri use outside the etiologically relevant time window, no increased effect was observed, adding biologic plausibility to our finding. Furthermore, because the effect was confined to the etiologically relevant time period, there is less concern for recall bias because it would likely be present for use reported at any time in pregnancy. the lack of an effect for non-SSri medications in the etiologically relevant window and the small risk for untreated depression suggest that the underlying depression is likely not responsible for the increased risk observed with SSri use.
if SSris do indeed increase the risk of clubfoot, the mechanism may involve the vasoconstrictive properties of serotonin. [17] [18] [19] [20] SSris function by blocking the reuptake of serotonin, thereby increasing serotonin levels. animal studies have found that serotonin is a uterine vasoconstrictor that leads to contractions of the umbilical artery, 17, 20 which results in a decrease of uterine artery blood flow in a dose-dependent fashion. 21 additionally, a study in pregnant ewes found that while serotonin infusions in the 3rd trimester led to uterine vasoconstriction, no systemic cardiovascular response was observed; therefore, serotonin may have a selective effect on the uterine vasculature. 22 given that clubfoot has been hypothesized to be the result of a vascular disruption, 23-25 a possible pathway for the pathogenesis of clubfoot may be through the vasoconstriction from higher levels of circulating serotonin because of SSri use. the present study is the largest population-based study of idiopathic clubfoot cases to date. the use of orthopedic medical records and information on treatment ensured that the cases were structural clubfoot, rather than positionaltype clubfoot. When orthopedic records were not available, we used the maternal report of 3 or more castings, which we found to have a high sensitivity when compared with orthopedic records. Furthermore, this study was designed specifically to assess medication use in relation to clubfoot, and one of its strengths is the detailed information on illness and medication history collected by the study nurses within 1 year of the infant's birth. One limitation was the small numbers of mothers exposed to some specific SSris, which resulted in unstable Or estimates for those drugs. in addition, we asked mothers about "depression or anxiety" as one question in our questionnaire and therefore were not able to determine whether the medications they reported were used specifically for depression or specifically for anxiety. However, not only can it be difficult to differentiate between depression and anxiety in general, these conditions often occur as comorbidities. 26 although we controlled for a large number of variables, we cannot rule out the possibility of confounding from unmeasured factors. Of particular concern is confounding by the underlying condition. to assess this possibility, we considered both untreated depression and depression treated by drugs other than SSris and found little evidence of confounding by indication. inaccurate recall of medications or depression histories may also be of concern, although it is less likely that mothers would forget using antidepressant medications because they are typically used on a regular basis; although moderate to severe depression is likely to be reported, less severe forms may not have been recognized or diagnosed. Denial of exposure is a possibility, but for such under-reporting to explain the observed positive associations would require that a higher proportion of control mothers deny use compared with case mothers; this situation seems unlikely.
in conclusion, our data support and expand previous suggestions that SSri use in the 2nd and 3rd lunar months of pregnancy increases the risk of clubfoot, independent of maternal report of depression. although there was a suggestion of an elevated risk for sertraline, escitalopram, and particularly paroxetine, the estimate for paroxetine was unstable because of small numbers of exposed subjects.
